Pedro Valencia, VP, asset strategy leadership, oncology, AbbVie, discusses how early data from ABBV-706 shows up to 50% ...

A young university student whose repeated symptoms of stomachache, nausea, vomiting, and weight loss were dismissed by ...

Pedro Valencia, VP, asset strategy leadership, oncology, AbbVie, explains how the company partners with patient advocacy groups to identify unmet needs and prioritize patient-centered benefits in the ...

If approved, Cabometyx® would be the first and only systemic therapy approved in the European Union for previously treated ...

Zanzalintinib plus Tecentriq significantly improved overall survival versus Stivarga in previously treated metastatic ...

A new cancer treatment that delivers radiation directly to tumors by targeting two key markers simultaneously has been shown ...

Common isotopes include lutetium-177, actinium-225, gallium-68 (diagnostic), fluorine-18, and radium-223. The therapy combines isotopic radiance with molecular targeting-e.g., PSMA in prostate cancer ...

Exelixis stock shines with 36% CABOMETYX sales growth, promising zanzalintinib market expansions, and raised 2025 guidance.

Although gastric cancer remains a major health issue both in the U.S. and worldwide, there has been a notable decline in ...

A student has shared her experience of being repeatedly dismissed by doctors, despite losing 10 kilos in just two months and ...

New trial results reveal zanzalintinib and atezolizumab significantly enhance survival in metastatic colorectal cancer, ...